Neurogene Inc. (NASDAQ:NGNE) CFO Sells $76,246.94 in Stock

Neurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic sold 4,501 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $16.94, for a total value of $76,246.94. Following the completion of the sale, the chief financial officer now owns 72,343 shares in the company, valued at $1,225,490.42. This trade represents a 5.86 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Neurogene Trading Up 1.0 %

Shares of NASDAQ NGNE opened at $16.87 on Tuesday. Neurogene Inc. has a one year low of $14.42 and a one year high of $74.49. The firm’s 50 day simple moving average is $17.66 and its two-hundred day simple moving average is $30.02.

Wall Street Analysts Forecast Growth

NGNE has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price target on shares of Neurogene in a report on Monday, November 25th. BMO Capital Markets dropped their target price on shares of Neurogene from $60.00 to $45.00 and set an “outperform” rating for the company in a research report on Wednesday, November 20th. Finally, William Blair restated an “outperform” rating on shares of Neurogene in a research report on Tuesday, November 19th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $60.83.

Hedge Funds Weigh In On Neurogene

Several institutional investors and hedge funds have recently made changes to their positions in the business. Jennison Associates LLC purchased a new stake in Neurogene during the third quarter valued at about $3,300,000. Charles Schwab Investment Management Inc. boosted its holdings in Neurogene by 2.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 30,317 shares of the company’s stock valued at $1,272,000 after acquiring an additional 741 shares during the period. FMR LLC grew its position in Neurogene by 912.4% during the 3rd quarter. FMR LLC now owns 731,801 shares of the company’s stock worth $30,706,000 after acquiring an additional 659,515 shares during the last quarter. BNP Paribas Financial Markets increased its stake in Neurogene by 192.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,170 shares of the company’s stock worth $91,000 after purchasing an additional 1,429 shares during the period. Finally, MetLife Investment Management LLC bought a new stake in Neurogene in the third quarter valued at approximately $254,000. Institutional investors own 52.37% of the company’s stock.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.